DESCRIPTION SECTION.

DESCRIPTION. AnazaoHealth compounds Stannous-Pyrophosphate as sterile lyophilized powder for the preparation of Tc99m Pyrophosphate. Each 10 ml reaction vial contains: 27.6 milligrams sodium pyrophosphate decahydrate, 3.5 milligrams stannous chloride, all lyophilized under an atmosphere of nitrogen. Prior to lyophilization the pH is adjusted with hydrochloric acid. The pH of the reconstituted drug is between 4.5 and 7.5. No bacteriostatic preservative is present.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION. The recommended adult dose of Tc99m Pyrophosphate Injection is:5 to 15 mCi for skeletal imaging10 to 15 mCi for cardiac imagingone-third (0.33) to the entire vial contents, followed 15 to 20 mCi of sodium pertechnetate Tc 99m, for blood pool imaging. to 15 mCi for skeletal imaging. 10 to 15 mCi for cardiac imaging. one-third (0.33) to the entire vial contents, followed 15 to 20 mCi of sodium pertechnetate Tc 99m, for blood pool imaging.

INDICATIONS & USAGE SECTION.

INDICATIONS AND USAGE. Stannous Pyrophosphate is indicated as blood pool imaging agent which may be used for gated pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously, 15-30 minutes prior to intravenous administration of sodium pertechnetate Tc99m for in vivo red blood cell labeling, approximately 75 percent of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging.It is also indicated as skeletal imaging agent used to demonstrate areas of altered osteogenesis, and cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL. Figure 1. e247d821-figure-01.

SPL UNCLASSIFIED SECTION.

Dear Medical Professional,Per your order, we have compounded Stannous-Pyrophosphate as sterile lyophilized powder. The characteristics of this preparation are:.